INDIA AND OMAN PHARMACEUTICAL INDUSTRY MARKET ANALYSIS

India and Oman Pharmaceutical Industry Market, by Drug (Generic and Patented (Branded)), by Type (Prescription Drugs and Over the Counter Drugs), by Drug Class (Analgesics, Anesthetics, Antibacterials, Antidepressants, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Anticonvulsants, Antivirals, Anticoagulants, ACE inhibitors, Hormonal agents, Insulin, Contraceptives, Diuretics, Vaccines, and Others), by Application (Cardiovascular (Ischemic Heart Disease and Others), Hypertension, Musculoskeletal, Oncology, Anti-infective, Cirrhosis, Metabolic Disorder (Diabetes and Others), Weight Management, Central Nervous System, Genito-urinary, Kidney Disease, Gastrointestinal, Respiratory, Hematology, Dermatology, Ophthalmology, and Others (Nutraceutical, Dentals, and Gynecology)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Country (India and Oman) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Aug 2021
Code : CMI4569
Pages :465
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

High number of banned products
Campaigns against spurious drugs
Lack of national health insurance plan
Product recall due to non-conformity to the stability specifications

India & Oman Pharmaceutical Industry Market: Restraint

High number of banned products in India and lack of national health insurance plan in Oman are expected to hinder growth of the India & Oman pharmaceutical industry market. For instance, according to the Central Drugs Standard Control Organization and Directorate General of Health Services Ministry of Health & Family Welfare Government of India, banned drugs in 2018 include combinations of Nimesulide + Levocetrizine, Ofloxacin + Ornidazole Injection and Glucosamine + Ibuprofen due to their side effects and drug abuse situations. Whereas, lack of national health insurance plan in Oman leads to the expenses of the public healthcare system to be depended on the government, perpetuating reliance on state provisions and straining the government budget and is expected to hinder the growth of the market.